Artikel

You have free access to this content

Tuberkulose unter TNFα-Inhibitoren

Eine neue klinische Krankheitsentität

  1. Prof. Dr. Matthias Trautmann

Article first published online: 2 JAN 2012

DOI: 10.1002/pauz.201100457

Issue

Pharmazie in unserer Zeit

Pharmazie in unserer Zeit

Volume 41, Issue 1, pages 79–83, Januar 2012

Additional Information

How to Cite

Trautmann, M. (2012), Tuberkulose unter TNFα-Inhibitoren. Pharmazie in unserer Zeit, 41: 79–83. doi: 10.1002/pauz.201100457

Author Information

  1. Institut für Krankenhaushygiene, Klinikum Stuttgart, Kriegsbergstraße 60, 70174 Stuttgart

Publication History

  1. Issue published online: 2 JAN 2012
  2. Article first published online: 2 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (339K)

REFERENCES

  • 1
    Hess, S. et al., Life-threatening disseminated tuberculosis as a complication of TNFa-blockade in an adolescent. Eur. J. Pediatr. (2011), DOI: 10.1007/s00431-011-1501-y.
  • 2
    Choi, S.W. et al., A case of tuberculous arthritis following the use of etanercept. Korean J. Intern. Med. 24, (2009) 397–401.
  • 3
    Winthrop, K.L. et al., Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthr. Rheum. 52, (2005) 2968–2974.
    Direct Link:
  • 4
    Keane, J. et al., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, (2001) 1098–1104.
  • 5
    Tubach, F. et al., Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthr. Rheum. 60, (2009) 1884–1894.
    Direct Link:
  • 6
    Dixon, W.G. et al., Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69, (2010) 522–528.
  • 7
    Lin, P.L. et al., Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arth. Rheumat. 62, (2010) 340–350.
  • 8
    Miller, E.A., Ernst, J.D., Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J. Clin. Invest. 119, (2009) 1079–1082.
  • 9
    Diel, R. et al., Empfehlungen für das Tuberkulose-Screening vor Gabe von TNFa-Inhibitoren bei rheumatischen Erkrankungen. Z. Rheumatol. 68, (2009) 411–416.
  • 10
    Wallis, R.S., Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis. 22, (2009) 403–409.
  • 11
    Panknin, H.T., Trautmann, M., TNFa-Inhibitoren: Risiko der Reaktivierung latenter Infektionen. Krankenhauspharmazie 32, (2011) 176–179.
Get PDF (339K)